Abstract
Proinflammatory cytokines have been demonstrated to play a crucial role in the pathogenesis and physiopathology of various chronic inflammatory conditions including Crohns disease (CD). Among these cytokines, interleukin-6 (IL-6) must be especially important because increased serum concentrations of acute phase proteins, reduced level of serum albumin, and remarkable thrombocytosis are all well-explained by the increased level of IL-6. Moreover, IL-6 is capable of stimulating even IL-6 receptor (IL-6R) negative cells such as vascular endothelial cells when complexed to soluble form of IL-6R (sIL-6R), and serum level of IL-6 as well as sIL- 6R has been demonstrated to increase during inflammation. To investigate the therapeutic potential of IL-6 signaling blockade for CD, anti-IL-6R monoclonal antibody (mAb) was introduced to various murine models of colitis. Anti-IL-6R mAb successfully prevented wasting disease and the development of macroscopic and histological lesions. It suppressed the accumulation of ICAM-1 positive and Mac-1 positive cells in the lamina propria (LP) and the expression of ICAM-1 and VCAM-1 by vascular endothelial cells. Expansion of colonic and splenic CD4+ T cells was reduced as well as the colonic expression of tumor necrosis factor α (TNF-α), IL-1β, and interferon γ (IFN-γ) mRNA without affecting the production of transforming growth factor β (TGF-β), IL-10, and IL-4 mRNA. The treatment also suppressed established colitis by inducing LP T cell apoptosis. These results strongly suggest that specific targeting of IL-6 / sIL-6R pathway will be a promising new approach for the treatment of CD, and the clinical trial of humanized anti-IL-6R mAb is now under way.
Keywords: interleukin-6, soluble interleukin-6 receptor, gp130, monoclonal antibody, crohn disease, proinflammatory cytokine, adhesion molecule, apoptosis
Current Pharmaceutical Design
Title: Anti-Interleukin-6 Therapy for Crohns Disease
Volume: 9 Issue: 4
Author(s): H. Ito
Affiliation:
Keywords: interleukin-6, soluble interleukin-6 receptor, gp130, monoclonal antibody, crohn disease, proinflammatory cytokine, adhesion molecule, apoptosis
Abstract: Proinflammatory cytokines have been demonstrated to play a crucial role in the pathogenesis and physiopathology of various chronic inflammatory conditions including Crohns disease (CD). Among these cytokines, interleukin-6 (IL-6) must be especially important because increased serum concentrations of acute phase proteins, reduced level of serum albumin, and remarkable thrombocytosis are all well-explained by the increased level of IL-6. Moreover, IL-6 is capable of stimulating even IL-6 receptor (IL-6R) negative cells such as vascular endothelial cells when complexed to soluble form of IL-6R (sIL-6R), and serum level of IL-6 as well as sIL- 6R has been demonstrated to increase during inflammation. To investigate the therapeutic potential of IL-6 signaling blockade for CD, anti-IL-6R monoclonal antibody (mAb) was introduced to various murine models of colitis. Anti-IL-6R mAb successfully prevented wasting disease and the development of macroscopic and histological lesions. It suppressed the accumulation of ICAM-1 positive and Mac-1 positive cells in the lamina propria (LP) and the expression of ICAM-1 and VCAM-1 by vascular endothelial cells. Expansion of colonic and splenic CD4+ T cells was reduced as well as the colonic expression of tumor necrosis factor α (TNF-α), IL-1β, and interferon γ (IFN-γ) mRNA without affecting the production of transforming growth factor β (TGF-β), IL-10, and IL-4 mRNA. The treatment also suppressed established colitis by inducing LP T cell apoptosis. These results strongly suggest that specific targeting of IL-6 / sIL-6R pathway will be a promising new approach for the treatment of CD, and the clinical trial of humanized anti-IL-6R mAb is now under way.
Export Options
About this article
Cite this article as:
Ito H., Anti-Interleukin-6 Therapy for Crohns Disease, Current Pharmaceutical Design 2003; 9 (4) . https://dx.doi.org/10.2174/1381612033391900
DOI https://dx.doi.org/10.2174/1381612033391900 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Characteristics Other than the Diagnostic Criteria Associated with Metabolic Syndrome: An Overview
Current Vascular Pharmacology Calreticulin in the Heart: From Embryological Development to Cardiac Pathology.
Current Molecular Medicine Nano-Systems for Advanced Therapeutics and Diagnosis of Atherosclerosis
Current Pharmaceutical Design Cardioprotector Activity of an Esteroidal Saponin: A Scientific and Technological Prospection
Recent Patents on Biotechnology Current Anti-Inflammatory Therapies and the Potential of Secretory Phospholipase A2 Inhibitors in the Design of New Anti-Inflammatory Drugs: A Review of 2012 - 2018
Current Medicinal Chemistry Lipoproteins, Stroke and Statins
Current Vascular Pharmacology Torsades de Pointes in Patients with Polymyalgia Rheumatica
Current Pharmaceutical Design Biomarkers of Atrial Fibrillation in Metabolic Syndrome
Current Medicinal Chemistry <i>Momordica balsamina L</i>.: An Appraisal on Morphology, Ecological Diversity, Phytochemistry, Pharmacological and Biotechnological Applications
Current Traditional Medicine Antiplatelet Therapy in Children: Why So Different from Adults’?
Current Pharmaceutical Design Nanomaterial Based Approaches for the Diagnosis and Therapy of Cardiovascular Diseases
Current Pharmaceutical Design Anti-Cancer Drugs Targeting Fatty Acid Synthase (FAS)
Recent Patents on Anti-Cancer Drug Discovery Perioperative Management of Patients with Down Syndrome
Current Pediatric Reviews Adverse Cardiovascular Effects of Antirheumatic Drugs: Implications for Clinical Practice and Research
Current Pharmaceutical Design Flavones as a Privileged Scaffold in Drug Discovery: Current Developments
Current Organic Synthesis T Cell Response in Rheumatic Fever: Crossreactivity Between Streptococcal M Protein Peptides and Heart Tissue Proteins
Current Protein & Peptide Science Therapeutic Utilities of Pediatric Cardiac Catheterization
Current Cardiology Reviews Antiplatelet and Anticoagulation Strategies in the Prevention and Treatment of Ischemic Stroke
Current Pharmaceutical Design Influenza and Stroke Risk: A Key Target Not to be Missed?
Infectious Disorders - Drug Targets Skeletal Muscle in Cancer Cachexia: The Ideal Target of Drug Therapy
Current Cancer Drug Targets